Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab (BMS-
936558) and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
The purpose of this study to investigate the safety and efficacy of using nivolumab to treat subjects who have virus-associated tumors. Certain viruses that infect human cells have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drug nivolumab in human subjects who have the following types of viral-associated tumors: Gastric Cancer, nasopharyngeal carcinoma , cervical cancer, vaginal cancer, vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel Cell Carcinoma.
* Histopathologic confirmation of the following tumor types:
Merkel Cell Carcinoma
Gastric or Gastro-Esophageal junction carcinoma
Squamous cell carcinoma of the cervix, vagina, or vulva
Squamous cell carcinoma of the Head and Neck
* Measurable disease by CT or MRI
Multiple Tumor Types
Rom Leidner, M.D.
Bristol Myers Squibb (BMS)
- Oncology and Hematology Care Eastside
- Oncology and Hematology Care Westside